Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Feb;53(2):79-85.
doi: 10.1007/s00262-003-0445-0. Epub 2003 Nov 11.

Role of IL-13 in regulation of anti-tumor immunity and tumor growth

Masaki Terabe  1 , Jong Myun Park, Jay A Berzofsky
Affiliations
Review

Role of IL-13 in regulation of anti-tumor immunity and tumor growth

Masaki Terabe et al. Cancer Immunol Immunother. 2004 Feb.

Abstract

Major mediators of anti-tumor immunity are CD4(+) T(h)1 cells and CD8(+) cytotoxic T lymphocytes (CTLs). In tumor-bearing animals, the T(h)1- and CTL-mediated anti-tumor immunity is down-regulated in multiple ways. Better understanding of negative regulatory pathways of tumor immunity is crucial for the development of anti-tumor vaccines and immunotherapies. Since immune deviation toward T(h)2 suppresses T(h)1 development, it has been thought that induction affecting a T(h)2 immune response is one of the mechanisms that down-regulate effective tumor immune responses. Recent studies using T(h)2-deficient signal transducer and activator (Stat6) KO mice demonstrated that this hypothesis was the case. IL-13 is one of the T(h)2 cytokines that has very similar features to IL-4 through sharing some receptor components and Stat6 signal transduction. It has been thought that IL-13 is not as critical for immune deviation as IL-4 since it cannot directly act on T cells. However, recent studies of IL-13 reveal that this cytokine plays a critical role in many aspects of immune regulation. Studies from our lab and others indicate that IL-13 is central to a novel immunoregulatory pathway in which NKT cells suppress tumor immunosurveillance. Here we will describe biological properties and functions of IL-13, its role in the negative regulation of anti-tumor immunity, and effects of IL-13 on tumor cells themselves.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Receptors for IL-13 and IL-4. IL-4 and IL-13 share the type II IL-4R, which shares the IL-4Rα chain with the type I IL-4R as well. Both receptors use JAK1 and Stat6 for signal transduction, but differ in JAK2 and JAK3. The receptors also have different distributions among cell and tissue types. An additional high affinity receptor for IL-13, IL-13Rα2, has no known function at this time, but has served as a component of a soluble IL-13 inhibitor. See [16, 43] for more detailed treatment
Fig. 2a, b
Fig. 2a, b
IL-13 can inhibit anti-tumor immune response and enhance tumor growth. a Inhibitory role of IL-13 in anti-tumor immunity. Tumor antigen (glycolipid) presented by antigen-presenting cells via the CD1d molecule is recognized by and activates CD4+ NKT cells. The activated CD4+ NKT cell produces IL-13 to suppress CD8+ cytotoxic T cells (CTLs) that kill tumor cells. However, since T cells do not express the IL-13 receptors, we postulated intermediate cells that express the IL-13 receptors, that are activated by IL-13 to directly suppress CTL. (Based on Terabe et al. [66, 67] with permission.) b IL-13 is a growth factor for Hodgkin’s lymphoma. Hodgkin’s lymphoma makes IL-13. This IL-13 activates growth of Hodgkin’s lymphoma through the IL-13 receptor–Stat6 pathway in an autocrine fashion [61]. The IL-13 made by Hodgkin’s lymphoma can also suppress anti-tumor immune responses by the mechanism shown in a
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahlers Proc Natl Acad Sci USA. 2002;99:13020. doi: 10.1073/pnas.192251199. - DOI - PMC - PubMed
    1. Aman J Biol Chem. 1996;271:29265. doi: 10.1074/jbc.271.46.29265. - DOI - PubMed
    1. Berzofsky Nat Rev Immunol. 2001;1:209. - PubMed
    1. Bochner J Immunol. 1995;154:799. - PubMed
    1. Brown J Immunol. 1989;142:679. - PubMed